
📺 Tune in at 2PM as I talk with the House @WaysMeansCmte Health Subcommittee about high drug prices, PBMs, and rebates! 💊💵 gop-waysandmeans.house.gov/e…

PCP @BrighamWomens, researcher @PORTAL_Research studying 💊💰📈. Alum @BrighamMedRes @harvardmed @HarvardChanSPH @BrownUniversity. Views my own.

📺 Tune in at 2PM as I talk with the House @WaysMeansCmte Health Subcommittee about high drug prices, PBMs, and rebates! 💊💵 gop-waysandmeans.house.gov/e…

Really nice work @DrHussainL @bnrome! One quick point of reflection: It’s crazy how complicated it is in our country for so many people to figure out how to get help affording their meds…
💊 New study in JAMA provides clear steps busy clinicians & staff can take to help patients struggling to afford their prescription drugs! We include an algorithm based on the patient's health insurance status & drug type (brand vs. generic). READ: jamanetwork.com/journals/jam…

Important new piece from @DrHussainL @bnrome and the @PORTAL_Research team. The incredibly high cost of prescription 💊💊 has huge #Pharmacoequity implications given the unequal distribution of wealth in the US and globally. Useful strategies outlined. jamanetwork.com/journals/jam…

Analysis led by Dongzhe Hong in @Health_Affairs examined the patient & prescriber factors impacting US #biosimilar use from 2013-2022, including geography, patient age, prescriber type, & where the drug was administered. healthaffairs.org/doi/10.137…

In their new Forefront article, @suhas_gondi, @bnrome + @WillShrank from @BrighamWomens + @Humana argue that, as regulators consider how mergers involving PBMs affect competition, they should also consider the clinical and financial benefits for patients. bit.ly/3WvYEzt

I didn’t realize a new season of @succession was coming out so soon! nytimes.com/2024/07/24/busin…

Analysis: U.S. Patent Office software mistakes extend patent life for drugs statnews.com/pharmalot/2024/…

In @JAMAHealthForum, Catherine Hwang, @DrHussainL & @bnrome discuss state efforts to set drug spending targets. They outline the limitations of using this policy to address high drug spending, absent a more robust approach to improve affordability. jamanetwork.com/journals/jam…


Hmm, not sure Peter Rheinstein actually read the @CMSGov ref’s on this. I get that @statnews is wants a diverse group of options, but something like this should still be fact checked. statnews.com/2024/07/15/medi…

#ARM24 friends: Come by 308 at 11am to hear about Medicaid coverage of anti-obesity meds.

Great to see so many @BrighamMedRes alumni at #ARM! 💪 Others not pictured: @JessicaTLeeMD @joefigs2 @rkwadhera @LisaRotenstein @walidgellad @ml_barnett @JMichaelMcW @A_Schwa @ChristopherLCai

Happening at 930: Come see the freshest health policy research at #ARM24 in our late-breaking session "Prices policy: No surprises, transparency, and monthly caps!"

Do $35 insulin out-of-pocket caps work??? Find out at 9:30 in 321-323.
Planning your #ARM24 Sunday? Come say hi. I’ll be sharing presenting some exciting data about the Inflation Reduction Act at 9am in room 321-323! And to bookmark the day, I’ll be sharing some one at the 8am and 5pm poster sessions.

Planning your #ARM24 Sunday? Come say hi. I’ll be sharing presenting some exciting data about the Inflation Reduction Act at 9am in room 321-323! And to bookmark the day, I’ll be sharing some one at the 8am and 5pm poster sessions.
